5
Emergy Phaarma
524812 BSE
Emergy Phaarma
Healthcare BSE: 524812 Pharmaceuticals & Biotechnology
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
1- Company has low interest coverage ratio.
Growth Rate
Net Income Growth
-380%
Quarterly Results
| Particulars | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 91.09 | 41.16 | 91.67 | 143 | 115 | 45.64 | 97.92 | 168 | 122 | 68.44 | 115 | 171 | 141 |
| Expenses | 87.61 | 83.64 | 98.02 | 143 | 153 | 150 | 91.28 | 121 | 136 | 129 | 90.92 | 141 | 143 |
| Operating Profit | 3.48 | -42.48 | -6.35 | -0.24 | -37.58 | -104 | 6.64 | 46.67 | -13.46 | -60.83 | 24.06 | 29.61 | -1.67 |
| OPM % | 3.82% | -103.21% | -6.93% | -0.17% | -32.58% | -228.53% | 6.78% | 27.85% | -10.99% | -88.88% | 20.93% | 17.32% | -1.18% |
| Other Income | 3.47 | 1.07 | 4.54 | 8.07 | 0.91 | 7.82 | 0.75 | 0.79 | 16.52 | 15.04 | 1.53 | 2.53 | 2.71 |
| Interest | 1.97 | 2.74 | 3.43 | 6.03 | 3.05 | 4.57 | 5.08 | 6.19 | 5.65 | 5.68 | 4.32 | 5.82 | 3.87 |
| Depreciation | 4.72 | 4.36 | 6.03 | 5.92 | 5.42 | 4.54 | 5.23 | 4.89 | 4.54 | 4.24 | 5.25 | 5.23 | 4.63 |
| PBT | 0.26 | -48.51 | -11.27 | -4.12 | -45.14 | -106 | -2.92 | 36.38 | -7.13 | -55.71 | 16.02 | 21.09 | -7.46 |
| Tax % | -3553.85% | -11.94% | -15.88% | -6.8% | -1.82% | -20.96% | 1.03% | 28.53% | -86.54% | -24.39% | 10.36% | -0.28% | -4.56% |
| Net Profit | 9.5 | -42.72 | -9.48 | -3.84 | -44.32 | -83.47 | -2.95 | 25.99 | -0.96 | -42.12 | 14.35 | 21.16 | -7.12 |
| EPS in Rs | 9.04 | -40.66 | -9.02 | -3.65 | -42.18 | -79.44 | -2.81 | 24.73 | -0.91 | -40.09 | 13.66 | 20.14 | -6.78 |
Profit & Loss
| Particulars | Sep 2006 | Sep 2007 |
|---|---|---|
| Sales | 0 | 0 |
| Expenses | 0.09 | 0.03 |
| Operating Profit | -0.09 | -0.03 |
| Other Income | 0.28 | 0 |
| Interest | 0 | 0 |
| Depreciation | 0.24 | 0.21 |
| PBT | -0.05 | -0.24 |
| Tax % | 0% | 0% |
| Net Profit | -0.05 | -0.24 |
| Div. Payout % | 0% | 0% |
Balance Sheet
| Particulars | Sep 2006 | Sep 2007 |
|---|---|---|
| Equity Capital | 4.75 | 4.75 |
| Reserves | -11.86 | -12.1 |
| Borrowings | 8.39 | 8.42 |
| Other Liabilities | 0.78 | 0.78 |
| Total Liabilities | 2.06 | 1.85 |
| Fixed Assets | 2.04 | 1.83 |
| CWIP | 0 | 0 |
| Investments | 0 | 0 |
| Other Assets | 0.02 | 0.02 |
| Total Assets | 2.06 | 1.85 |
Cash Flow
| Particulars | Sep 2006 | Sep 2007 |
|---|---|---|
| Operating | -0.03 | -0.03 |
| Investing | 0 | 0 |
| Financing | 0.03 | 0.03 |
| Net Cash Flow | 0 | 0 |
| Free Cash Flow | -0.03 | -0.03 |
| CFO/OP | 33 | 100 |
Ratios
| Particulars | Sep 2006 | Sep 2007 |
|---|---|---|
| ROCE % | — | -20.43% |
Documents
1
Announcement Under Regulation 30- Agreement
12 Feb - To subscribe USD 1.5M optional convertible debentures of wholly-owned subsidiary; 7.90% p.a.; board approved Feb 10, 2026. 12 Feb - To subscribe USD 1.5M optional convertible debentures of wholly-owned subsidiary; 7.90% p.a.; board approved Feb 10, 2026.
2
Board Meeting Outcome for Outcome Of Board Meeting
10 Feb - Approved unaudited Q3 and nine-month results (Dec 31, 2025); approved up to USD 2.00M OCD subscription to WOS. 10 Feb - Approved unaudited Q3 and nine-month results (Dec 31, 2025); approved up to USD 2.00M OCD subscription to WOS.
3
Financial Results For The Quarter Ended December 31, 2025
10 Feb - Unaudited Q3/9M results for Dec 31, 2025 approved; subscribe up to USD 2.00M OCD in DPTPL. 10 Feb - Unaudited Q3/9M results for Dec 31, 2025 approved; subscribe up to USD 2.00M OCD in DPTPL.
4
Announcement under Regulation 30 (LODR)-Newspaper Publication
7 Feb - Announcement regarding special window for transfer & dematerialisation of physical shares. 7 Feb - Announcement regarding special window for transfer & dematerialisation of physical shares.
5
Board Meeting Intimation for Board Meeting Intimation For Unaudited Financial Results For The Quarter And Nine Months Ended 31St December, 2025.
30 Jan - Board meeting 10 Feb 2026 to consider unaudited results for quarter and nine months ended 31 Dec 2025; trading window closed. 30 Jan - Board meeting 10 Feb 2026 to consider unaudited results for quarter and nine months ended 31 Dec 2025; trading window closed.
Frequently Asked Questions about Emergy Phaarma
Where is Emergy Phaarma Ltd (524812) listed?
Emergy Phaarma Ltd trades under code 524812 on the BSE.
Which sector does Emergy Phaarma Ltd belong to?
Emergy Phaarma Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
Company Information
Website somanigroup.com
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524812.md for Emergy Phaarma Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.